NSCLC< lung cancer

Showing 2 posts of 2 posts found.

Roche’s entrectinib shrinks lung tumours with two-year response duration

September 25, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …

Roche unveils strong combination treatment data in lung cancer

November 20, 2017
Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …

Latest content